Compare CCL & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCL | GEHC |
|---|---|---|
| Founded | 1972 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Computer Software: Prepackaged Software |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2B | 38.9B |
| IPO Year | 1987 | N/A |
| Metric | CCL | GEHC |
|---|---|---|
| Price | $33.98 | $80.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 12 |
| Target Price | $36.05 | ★ $91.08 |
| AVG Volume (30 Days) | ★ 20.1M | 3.9M |
| Earning Date | 03-20-2026 | 02-04-2026 |
| Dividend Yield | ★ 1.91% | 0.17% |
| EPS Growth | ★ 40.51 | 4.84 |
| EPS | 2.02 | ★ 4.55 |
| Revenue | ★ $26,622,000,000.00 | $20,625,000,000.00 |
| Revenue This Year | $5.64 | $5.90 |
| Revenue Next Year | $3.67 | $4.52 |
| P/E Ratio | ★ $15.58 | $18.09 |
| Revenue Growth | ★ 6.40 | 4.84 |
| 52 Week Low | $15.07 | $57.65 |
| 52 Week High | $33.15 | $94.80 |
| Indicator | CCL | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 60.00 | 54.43 |
| Support Level | $31.14 | $78.23 |
| Resistance Level | $32.61 | $85.54 |
| Average True Range (ATR) | 1.06 | 2.09 |
| MACD | 0.24 | 0.20 |
| Stochastic Oscillator | 77.37 | 68.23 |
Carnival is the largest global cruise company, with more than 90 ships in service. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe. It recently folded its P&O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted 14 million guests in 2024.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).